Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-401 + Pom/Dex in RRMM
NCT02661022Phase 2Terminated
- Sponsor
- Stemline Therapeutics
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 2, open-label trial of avacincaptad pegol in multiple myeloma (MM) (2 arms), sponsored by Stemline Therapeutics. Primary endpoints: Number of Patients With Dose-limiting Toxicities and Treatment-emergent Adverse Events, Number of Patients With Treatment-related Adverse Events up to 12 months and 1 more. Started Jan 2016; status: terminated.
02
Drugs
avacincaptad pegol
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02661022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661022.